Filanesib (ARRY-520) targets the kinesin spindle protein (KSP) with potential antineoplastic activity. ARRY-520 specifically inhibits KSP (kinesin-5 or Eg5), resulting in activation of the spindle assembly checkpoint, induction of cell cycle arrest during the mitotic phase, and consequently cell death in tumor cells that are actively dividing.

1781834-99-8

C22H23F5N4O4S

534.5

Filanesib trifluoroacetic acid;ARRY520 TFA;ARRY-520 TFA;ARRY 520 TFA;Filanesib TFA

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years